United Therapeutics (UTHR) Non-Current Debt (2017 - 2024)
Historic Non-Current Debt for United Therapeutics (UTHR) over the last 13 years, with Q2 2024 value amounting to $100.0 million.
- United Therapeutics' Non-Current Debt fell 8750.0% to $100.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $100.0 million, marking a year-over-year decrease of 8750.0%. This contributed to the annual value of $300.0 million for FY2023, which is 6250.0% down from last year.
- Latest data reveals that United Therapeutics reported Non-Current Debt of $100.0 million as of Q2 2024, which was down 8750.0% from $200.0 million recorded in Q1 2024.
- In the past 5 years, United Therapeutics' Non-Current Debt ranged from a high of $800.0 million in Q1 2020 and a low of $100.0 million during Q2 2024
- Moreover, its 5-year median value for Non-Current Debt was $800.0 million (2020), whereas its average is $683.3 million.
- Its Non-Current Debt has fluctuated over the past 5 years, first soared by 3333.33% in 2020, then plummeted by 8750.0% in 2024.
- Quarter analysis of 5 years shows United Therapeutics' Non-Current Debt stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then tumbled by 62.5% to $300.0 million in 2023, then tumbled by 66.67% to $100.0 million in 2024.
- Its Non-Current Debt was $100.0 million in Q2 2024, compared to $200.0 million in Q1 2024 and $300.0 million in Q4 2023.